GE Healthcare Signs Global Molecular Diagnostic Agreement To Advance Respiratory Drug Development

Main Category: Respiratory / Asthma
Also Included In: MRI / PET / Ultrasound
Article Date: 07 May 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions

GE Healthcare, a subsidiary of the General Electric Company (NYSE:GE) announced that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development. Under terms of the agreement, Merck will be granted access to Spin Signal TechnologyTM (SST) utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under investigation by GE Healthcare to provide high speed, quantitative imaging of the lung using Magnetic Resonance Imaging (MRI). GE Healthcare originally licensed this technology from Princeton University.

This technology is being evaluated to determine if it can provide more sensitive information than currently available tests on how diseased lungs function, by using xenon, a gas that can be modified with the SST to be detectable with MRI. With this technology, MRI delivers images that may provide clinical value by allowing regional imaging of disease. This information could enhance that provided by FEV1, the volume exhaled during the first second of a forced expiratory maneuver.

"Imaging the lungs has traditionally been challenging for pharmaceutical companies needing to assess the impact of developmental therapies on lung function.This agreement enables the companies involved in this collaboration to assess in real-time the effect of potential therapeutics in animal models," said Jonathan Allis, head of the Global Imaging Network at GE Healthcare.

This agreement is part of GE Healthcare's strategy of helping to accelerate the development of new therapeutics by improving Pharma access to novel molecular imaging agents to assess the impact of potential drugs in animal models and, when appropriate, human subjects.

"With cutting edge molecular diagnostic capabilities across all modalities, GE Healthcare is well positioned to work with pharmaceutical companies to tailor therapeutic assessment programs to further their drug development," said Kim Gallagher, head of External Scientific Affairs in the Medical Diagnostics Division of GE Healthcare. "By joining this development collaboration, Merck will have full access to the SST and hyperpolarized Xenon 129 trial data to monitor its potential and plan for its possible incorporation in therapy trials. We look forward to initiating further agreements with key pharmaceutical companies in the coming year in other disease areas."

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.

GE Healthcare